MELK is not necessary for the proliferation of basal-like breast cancer cells.
Huang, H.T., Seo, H.S., Zhang, T., Wang, Y., Jiang, B., Li, Q., Buckley, D.L., Nabet, B., Roberts, J.M., Paulk, J., Dastjerdi, S., Winter, G.E., McLauchlan, H., Moran, J., Bradner, J.E., Eck, M.J., Dhe-Paganon, S., Zhao, J.J., Gray, N.S.(2017) Elife 6
- PubMed: 28926338 
- DOI: 10.7554/eLife.26693
- Primary Citation of Related Structures:  
5TWL, 5TWU, 5TWY, 5TWZ, 5TX3 - PubMed Abstract: 
Thorough preclinical target validation is essential for the success of drug discovery efforts. In this study, we combined chemical and genetic perturbants, including the development of a novel selective maternal embryonic leucine zipper kinase (MELK) inhibitor HTH-01-091, CRISPR/Cas9-mediated MELK knockout, a novel chemical-induced protein degradation strategy, RNA interference and CRISPR interference to validate MELK as a therapeutic target in basal-like breast cancers (BBC) ...